Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bellicum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Bellicum Pharmaceuticals Secures USD94.36 Million in Series C Round of Funding 13
Bellicum Pharma Raises USD55 Million In Series C Financing 15
Bellicum Pharma Raises US$14.7 Million In Extended Series B Financing 17
Bellicum Pharma Raises US$20 Million In Series B Financing 18
Partnerships 19
Kiromic Enters into Agreement with Bellicum Pharma 19
Adaptimmune Therapeutics Enters into Co-development Agreement with Bellicum Pharma 20
Bellicum Pharma Enters into Co-Development Agreement with Ospedale Pediatrico Bambino Gesu 21
Bellicum Pharma Enters into Research Agreement with Leiden University Medical Center 22
Licensing Agreements 23
Bellicum Pharmaceuticals Enters Into Licensing Agreement with Baylor College of Medicine 23
Bellicum Pharma Enters into Licensing Agreements with Baylor College of Medicine 24
Bellicum Pharma Enters into Licensing Agreement with Agensys 25
Bellicum Pharma Enters into License Agreement with Biovec Pharma 26
Bellicum Pharma Enters into Licensing Agreement with Leiden University Medical Center 27
Bellicum Pharma Enters into Licensing Agreement with Baylor College of Medicine 29
Equity Offering 30
Bellicum Pharma to Raise up to USD60 Million in Public Offering of Shares 30
Bellicum Pharma Raises USD69 Million in Public Offering of Shares 31
Bellicum Pharma Plans to Raise up to USD63.7 Million in Public Offering of Shares 33
Bellicum Pharma Raises USD69 Million in Public Offering of Shares 34
Bellicum Pharma Raises USD160.6 Million in IPO 36
Bellicum Pharmaceuticals Inc – Key Competitors 38
Bellicum Pharmaceuticals Inc – Key Employees 39
Bellicum Pharmaceuticals Inc – Locations And Subsidiaries 40
Head Office 40
Recent Developments 41
Financial Announcements 41
Aug 07, 2018: Bellicum Pharmaceuticals reports second quarter 2018 financial results 41
May 08, 2018: Bellicum Pharmaceuticals Announces First Quarter 2018 Financial Results 43
Mar 13, 2018: Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017 45
Nov 07, 2017: Bellicum Reports Third Quarter 2017 Financial Results 47
Aug 08, 2017: Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 49
May 08, 2017: Bellicum Pharmaceuticals Reports First Quarter 2017 Financial Results 51
Mar 13, 2017: Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 53
Corporate Communications 55
Jul 16, 2018: Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer 55
Feb 21, 2018: Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors 56
Feb 05, 2018: Bellicum Pharmaceuticals Names Dr. William Grossman as Chief Medical Officer 57
Aug 03, 2017: Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer 58
May 15, 2017: Bellicum Pharmaceuticals Announces Management Changes 59
Jan 31, 2017: Bellicum Pharmaceuticals appoints president, CEO and board member 60
Product News 61
02/22/2017: Bellicum Presents Updated Clinical Results at 2017 BMT Tandem Meetings on BPX-501 in Orphan Inherited Blood Disorders and Hematologic Cancers 61
01/31/2017: Bellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of Growth 62
Product Approvals 63
Jan 30, 2018: Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States 63
Clinical Trials 64
Feb 21, 2017: Bellicum Announces Initiation of Patient Dosing with Controllable CAR T-Cell Product Candidate 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellicum Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Bellicum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bellicum Pharmaceuticals Secures USD94.36 Million in Series C Round of Funding 13
Bellicum Pharma Raises USD55 Million In Series C Financing 15
Bellicum Pharma Raises US$14.7 Million In Extended Series B Financing 17
Bellicum Pharma Raises US$20 Million In Series B Financing 18
Kiromic Enters into Agreement with Bellicum Pharma 19
Adaptimmune Therapeutics Enters into Co-development Agreement with Bellicum Pharma 20
Bellicum Pharma Enters into Co-Development Agreement with Ospedale Pediatrico Bambino Gesu 21
Bellicum Pharma Enters into Research Agreement with Leiden University Medical Center 22
Bellicum Pharmaceuticals Enters Into Licensing Agreement with Baylor College of Medicine 23
Bellicum Pharma Enters into Licensing Agreements with Baylor College of Medicine 24
Bellicum Pharma Enters into Licensing Agreement with Agensys 25
Bellicum Pharma Enters into License Agreement with Biovec Pharma 26
Bellicum Pharma Enters into Licensing Agreement with Leiden University Medical Center 27
Bellicum Pharma Enters into Licensing Agreement with Baylor College of Medicine 29
Bellicum Pharma to Raise up to USD60 Million in Public Offering of Shares 30
Bellicum Pharma Raises USD69 Million in Public Offering of Shares 31
Bellicum Pharma Plans to Raise up to USD63.7 Million in Public Offering of Shares 33
Bellicum Pharma Raises USD69 Million in Public Offering of Shares 34
Bellicum Pharma Raises USD160.6 Million in IPO 36
Bellicum Pharmaceuticals Inc, Key Competitors 38
Bellicum Pharmaceuticals Inc, Key Employees 39
List of Figures
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellicum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bellicum Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10